文献速递消化系统肿瘤

幽门螺杆菌感染及治疗对结直肠癌的影响:一项大规模全国性队列研究

Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.
PubMed 文献 · J Clin Oncol · 2024-03-01

该回顾性队列分析纳入1999至2018年间完成幽门螺杆菌检测的812,736名美国退伍军人,其中205,178人(25.2%)检测阳性。幽门螺杆菌阳性者结直肠癌发病和死亡风险均高于阴性者;在阳性者中,未经治疗者发病和死亡风险高于治疗者,绝对风险降低0.23%–0.35%。

要点

  • 幽门螺杆菌阳性与结直肠癌发病风险升高相关(校正HR 1.18,95%CI 1.12–1.24)及死亡风险升高相关(校正HR 1.12,95%CI 1.03–1.21)。
  • 在幽门螺杆菌阳性者中,未治疗者结直肠癌发病风险高于治疗者(校正HR 1.23,95%CI 1.13–1.34),死亡风险亦高于治疗者(校正HR 1.40,95%CI 1.24–1.58)。
  • 治疗与未治疗相比,结直肠癌绝对风险降低0.23%–0.35%,随访至15年。

核心结论

  • 幽门螺杆菌阳性可能与结直肠癌发病率和死亡率的小幅但统计学显著的升高相关;未治疗者、尤其是确诊活动性感染者风险似乎最高。

研究设计与样本

  • 回顾性队列分析,纳入1999至2018年间在美国退伍军人健康管理局内完成幽门螺杆菌检测的成人,共812,736人,其中205,178人(25.2%)检测阳性。

主要发现

  • 幽门螺杆菌阳性 vs 阴性:结直肠癌发病风险校正HR 1.18(95%CI 1.12–1.24),死亡风险校正HR 1.12(95%CI 1.03–1.21)。
  • 在幽门螺杆菌阳性者中,未治疗 vs 治疗:结直肠癌发病风险校正HR 1.23(95%CI 1.13–1.34),死亡风险校正HR 1.40(95%CI 1.24–1.58)。
  • 治疗 vs 未治疗:结直肠癌绝对风险降低0.23%–0.35%,随访至15年。
  • 限于非血清学检测者的分析中,结果更为明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Helicobacter pylori is the most common cause of infection-associated cancer worldwide. We aimed to evaluate the impact of H. pylori infection and treatment on colorectal cancer (CRC) incidence and mortality. PATIENTS: US Veterans who completed H. pylori testing between 1999 and 2018. METHODS: We conducted a retrospective cohort analysis among adults within the Veterans Health Administration who completed testing for H. pylori. The primary exposures were (1) H. pylori test result (positive/negative) and (2) H. pylori treatment (untreated/treated) among H. pylori-positive individuals. The primary outcomes were CRC incidence and mortality. Follow-up started at the first H. pylori testing and continued until the earliest of incident or fatal CRC, non-CRC death, or December 31, 2019. RESULTS: Among 812,736 individuals tested for H. pylori, 205,178 (25.2%) tested positive. Being H. pylori-positive versus H. pylori-negative was associated with higher CRC incidence and mortality. H. pylori treatment versus no treatment was associated with lower CRC incidence and mortality (absolute risk reduction 0.23%-0.35%) through 15-year follow-up. Being H. pylori-positive versus H. pylori-negative was associated with an 18% (adjusted hazard ratio [adjusted HR], 1.18 [95% CI, 1.12 to 1.24]) and 12% (adjusted HR, 1.12 [95% CI, 1.03 to 1.21]) higher incident and fatal CRC risk, respectively. Individuals with untreated versus treated H. pylori infection had 23% (adjusted HR, 1.23 [95% CI, 1.13 to 1.34]) and 40% (adjusted HR, 1.40 [95% CI, 1.24 to 1.58]) higher incident and fatal CRC risk, respectively. The results were more pronounced in the analysis restricted to individuals with nonserologic testing. CONCLUSION: H. pylori positivity may be associated with small but statistically significant higher CRC incidence and mortality; untreated individuals, especially those with confirmed active infection, appear to be most at risk.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shah SC, Camargo MC, Lamm M, et al. Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort. J Clin Oncol. 2024. PMID: 38427927. doi:10.1200/JCO.23.00703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。